Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Receivables - Other (2016 - 2018)

Historic Receivables - Other for Regen BioPharma (RGBPP) over the last 5 years, with Q4 2018 value amounting to $5120.0.

  • Regen BioPharma's Receivables - Other fell 4930.19% to $5120.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $5120.0, marking a year-over-year decrease of 4930.19%. This contributed to the annual value of $20000.0 for FY2018, which is 1764.71% up from last year.
  • As of Q4 2018, Regen BioPharma's Receivables - Other stood at $5120.0, which was down 4930.19% from $7672.0 recorded in Q3 2018.
  • In the past 5 years, Regen BioPharma's Receivables - Other registered a high of $102852.0 during Q2 2017, and its lowest value of $14.0 during Q2 2014.
  • In the last 5 years, Regen BioPharma's Receivables - Other had a median value of $3171.0 in 2017 and averaged $11291.7.
  • Its Receivables - Other has fluctuated over the past 5 years, first soared by 762142.86% in 2015, then crashed by 9265.06% in 2018.
  • Quarter analysis of 5 years shows Regen BioPharma's Receivables - Other stood at $493.0 in 2014, then surged by 240.97% to $1681.0 in 2015, then skyrocketed by 71.21% to $2878.0 in 2016, then skyrocketed by 250.9% to $10099.0 in 2017, then crashed by 49.3% to $5120.0 in 2018.
  • Its Receivables - Other stands at $5120.0 for Q4 2018, versus $7672.0 for Q3 2018 and $7559.0 for Q2 2018.